Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 12/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19966900 | 0.81 | PRKDC (0.40) | USP2ALDH1A1HPGDKDM4ECYP1A2 | |
| SCHEMBL19960978 | 0.76 | HTR2A (0.36) | LMNAKCNK3ALDH1A1MAPTHPGD | |
| SCHEMBL19960990 | 0.68 | KCNQ2 (0.34) | LMNAALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL19966901 | 0.67 | MAPT (0.36) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL19960991 | 0.67 | PER2 (0.44) | KCNK3ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL19940597 | 0.63 | GABRA1 (0.56) | MAPTL3MBTL1NPSR1 | |
| SCHEMBL18202158 | 0.62 | PRKDC (0.42) | LMNAUSP2ALDH1A1TDP1MEN1 | |
| SCHEMBL25818344 | 0.61 | KCNK3 (0.34) | KCNK3ALDH1A1MAPTTDP1HPGD | |
| SCHEMBL21718404 | 0.60 | GABRA1 (0.52) | LMNAHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL19532829 | 0.59 | CYP2A13 (0.67) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | LMNA 4865/4885USP2 3204/4885KCNK3 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.